Alcon Laboratories, Inc. v. Pharmacia Corp.

225 F. Supp. 2d 340, 54 Fed. R. Serv. 3d 11, 2002 U.S. Dist. LEXIS 14284, 2002 WL 1792060
CourtDistrict Court, S.D. New York
DecidedAugust 2, 2002
Docket01 Civ. 2989(WHP)
StatusPublished
Cited by12 cases

This text of 225 F. Supp. 2d 340 (Alcon Laboratories, Inc. v. Pharmacia Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Alcon Laboratories, Inc. v. Pharmacia Corp., 225 F. Supp. 2d 340, 54 Fed. R. Serv. 3d 11, 2002 U.S. Dist. LEXIS 14284, 2002 WL 1792060 (S.D.N.Y. 2002).

Opinion

MEMORANDUM AND ORDER

PAULEY, District Judge.

Plaintiffs Alcon Laboratories, Inc. and Alcon Manufacturing, Ltd. (collectively “Alcon”) filed this action against defendants Pharmacia Corporation and Phar-macia & Upjohn Company (collectively “Pharmacia”) and the Trustees of Columbia University (“Columbia”), seeking a declaratory judgment that their glaucoma treatment product, marketed under the brand-name Travatan, does not infringe on U.S. Patent No. 4,599,353 (the “ ’353 patent”) and that the ’353 patent is invalid. The ’353 patent, which was issued in 1986, is owned by Columbia and exclusively licensed to Pharmacia. It covers the use of prostaglandins for treating glaucoma.

Columbia moves for a protective order quashing a subpoena and precluding the deposition of John P. White, Esq., its lead trial counsel and the lawyer responsible for the prosecution of the ’353 patent for Columbia over twenty years ago. For the reasons set forth below, Columbia’s motion is denied in its entirety.

*342 Alcon subpoenaed White for a deposition on issues concerning inventorship of the ’353 patent and representations made to the Patent and Trademark Office (“PTO”), including White’s written argument submitted to the PTO. Alcon contends that White’s testimony is relevant and crucial to its inequitable conduct defense concerning inventorship as that defense is predicated on multiple events, most or all of which involve White as a participant or possible percipient witness.

The Federal Rules of Civil Procedure do not prohibit the deposition of an opposing counsel, yet they are strongly disfavored. See United States v. Yonkers Bd. of Educ., 946 F.2d 180, 185 (2d Cir.1991); see also Hickman v. Taylor, 329 U.S. 495, 516, 67 S.Ct. 385, 91 L.Ed. 451 (1947) (Jackson, J., concurring) (“Discovery was hardly intended to enable a learned profession to perform its functions ... on wits borrowed from the adversary.”); Gould, Inc. v. Mitsui Mining & Smelting Co., Ltd., 825 F.2d 676, 680 n. 2 (2d Cir.1987) (noting that it is generally well regarded that the tactic of seeking discovery from adversary counsel is disfavored, but is not a talisman for the resolution of all controversies of this nature).

This presumption is based on the recognition that even a deposition of counsel limited to relevant and nonprivileged information risks disrupting the attorney-client relationship and impeding the litigation.... Nevertheless, depositions of opposing counsel are not categorically barred. Rather, the request to depose a party’s attorney must be weighed by balancing, generally speaking, the necessity for such discovery in the circumstances of the case against its potential to oppress the adverse party and to burden the adversary process itself.

Madanes v. Madanes, 199 F.R.D. 135, 151 (S.D.N.Y.2001). In Shelton v. American Motors Corp., 805 F.2d 1323 (8th Cir.1986), the Eighth Circuit held that deposing opposing counsel “should be limited to where the party seeking to take the deposition has shown that (1) no other means exist to obtain the information than to depose opposing counsel; (2) the information sought is relevant and nonprivileged; and (3) the information is crucial to the preparation of the case.” Shelton, 805 F.2d at 1327 (citations omitted).

Although the Second Circuit has not expressly adopted the Shelton standard, it expressed agreement with the principles expressed by the Eighth Circuit. See Yonkers Bd. of Educ., 946 F.2d at 185; Gould, 825 F.2d at 680 n. 2. Further, the Shelton test has been widely followed by district courts in this Circuit. See, e.g., Madanes, 199 F.R.D. at 151; Maher v. Monahan, No. 98 Civ. 2319(JGK)(MHD), 2000 WL 777877, at *3-4 (S.D.N.Y. June 15, 2000); U.S. Fidelity & Guar. v. Braspetro Oil Services Co., Nos. 97 Civ. 6124(JGK)(THK), 98 Civ. 3099(JGK)(THK), 2000 WL 1253262, at *1 (S.D.N.Y. Sept. 1, 2000); Pereira v. United Jersey Bank, Nos. 94 Civ. 1565(LAP), 94 Civ. 1844(LAP), 1997 WL 773716, at *7-8 (S.D.N.Y. Dec. 11, 1997); Niagara Mohawk Power Corp. v. Stone & Webster Eng’g Corp., 125 F.R.D. 578, 594 (N.D.N.Y.1989).

Columbia contends that the practice of deposing opposing party’s attorneys is decried absent some showing of “compelling need,” and that Alcon has failed to satisfy the prerequisite compelling need for White’s deposition established in Shelton. Columbia argues that “the mere request to depose a party’s attorney constitutes good cause for obtaining a protective order.” N.F.A. Corp. v. Riverview Narrow Fabrics, 117 F.R.D. 83, 85 (M.D.N.C.1987).

Alcon responds that Shelton is inapplicable here because the Eighth Circuit limited that holding in Pamida, Inc. v. E.S. *343 Originals, Inc., 281 F.3d 726 (8th Cir.2002). In Pamida the Eighth Circuit held that

[t]he Shelton test was intended to protect against the ills of deposing counsel in a pending case which could potentially lead to the disclosure of the attorney’s litigation strategy.... But Shelton was not intended to provide heightened protection to attorneys who represented a client in a completed case and then also happened to represent that same client in a pending case where the information known only by the attorneys regarding the prior concluded case was crucial.

Pamida, 281 F.3d at 730. The Eighth Circuit further noted that protection for opposing counsel “only applies because opposing counsel is counsel in the instant case and not because opposing counsel had represented the client in the concluded case. Therefore, the Shelton test applies only to the instant case, not to the concluded case.” Pamida, 281 F.3d at 730. Thus, Alcon contends, Shelton is inapposite where an attorney representing a client in a completed case also happens to represent that same client in a subsequent ease where the information known only by the attorney regarding the prior concluded case is crucial. This Court need not address whether Pamida effectively limits Shelton to cases where the subject matter of the testimony sought is the subject matter underlying the instant case because Columbia’s application fails even when Shelton is applied.

Under Shelton, Alcon must show that no other means exist to obtain the information it seeks other than to depose opposing counsel, and that the information sought is relevant, non-privileged and crucial to its case. Shelton, 805 F.2d at 1327.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Probert v. Clorox Co.
258 F.R.D. 491 (D. Utah, 2009)
Sea Tow International, Inc. v. Pontin
246 F.R.D. 421 (E.D. New York, 2007)
Giannicos v. Bellevue Hospital Medical Center
7 Misc. 3d 403 (New York Supreme Court, 2005)
King-Fisher Co. v. United States
58 Fed. Cl. 570 (Federal Claims, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
225 F. Supp. 2d 340, 54 Fed. R. Serv. 3d 11, 2002 U.S. Dist. LEXIS 14284, 2002 WL 1792060, Counsel Stack Legal Research, https://law.counselstack.com/opinion/alcon-laboratories-inc-v-pharmacia-corp-nysd-2002.